Patent Armory v. HCA Healthcare: Five Call Routing Patents, Dismissed With Prejudice in 67 Days
Patent Armory, Inc. filed suit against HCA Healthcare, Inc. in the Western District of Texas asserting five patents covering intelligent call routing, telephony control, and auction-based entity matching. The case ended with a voluntary dismissal with prejudice just 67 days after filing — before HCA Healthcare filed any answer or dispositive motion.
Five telephony patents, one rapid dismissal — what happened in W.D. Texas
On December 19, 2024, Patent Armory, Inc. filed an infringement action against HCA Healthcare, Inc. in the Western District of Texas (Case No. 7:24-cv-00335), asserting five U.S. patents: US9456086B1, US10491748B1, US7269253B1, US7023979B1, and US10237420B1. The patents collectively cover intelligent communication routing systems, telephony control with intelligent call routing, and a method and system for matching entities in an auction — technology domains directly relevant to large-scale healthcare call center and patient communication infrastructure.
The case closed just 67 days later, on February 24, 2025, following Patent Armory’s filing of a Notice of Voluntary Dismissal With Prejudice on February 21, 2025. The dismissal invoked Federal Rule of Civil Procedure 41(a)(1)(A)(i), which permits a plaintiff to terminate an action unilaterally before the defendant serves an answer or a motion for summary judgment. Because HCA Healthcare had not yet served either, the dismissal was self-effectuating — no court order was required to terminate the case, and the Court’s order was confirmatory in nature. Each party was ordered to bear its own costs.
The 67-day lifespan is notably short even by the standard of quickly-resolved patent assertions, and the with-prejudice designation is legally significant: Patent Armory is permanently barred from reasserting these five patents against HCA Healthcare on the same claims. The public record does not disclose whether a confidential settlement drove the dismissal or whether Patent Armory concluded the case lacked merit to pursue. The absence of any answer or summary judgment motion from HCA Healthcare means the patents’ validity and claim scope were never adjudicated on the merits.
Filing to Voluntary dismissal in 67 days
67 days — closed well before the median district court patent case duration of 2+ years
Dismissed with prejudice: what Rule 41 means for both parties
Rule 41(a)(1)(A)(i): a self-executing dismissal tool
Federal Rule 41(a)(1)(A)(i) allows a plaintiff to dismiss an action as of right — without court approval — by filing a notice before the defendant serves an answer or a motion for summary judgment. Because HCA Healthcare had done neither, Patent Armory’s notice was self-effectuating under Fifth Circuit precedent (In re Amerijet, 785 F.3d 967). The court’s order was administrative, not dispositive.
Rule 41(a)(1)(A)(i) dismissalWith prejudice chosen: a permanent bar on these claims
Patent Armory specifically elected dismissal with prejudice — the more consequential option. A dismissal without prejudice would preserve the right to refile; with prejudice extinguishes it permanently. The public record does not disclose why the with-prejudice designation was chosen. It is consistent with a confidential settlement, a strategic concession, or a decision that litigation was not viable — but none of these can be confirmed from available filings.
Permanent bar on refilingPatent Armory loses enforcement rights against HCA Healthcare
By dismissing with prejudice, Patent Armory permanently relinquishes the right to assert US9456086B1, US10491748B1, US7269253B1, US7023979B1, and US10237420B1 against HCA Healthcare on the same claims. The patents themselves survive and remain enforceable against third parties — but HCA Healthcare is effectively immunised from future assertions on these specific claims by this plaintiff.
Patents survive; HCA shieldedHCA Healthcare exits without admitting liability or paying declared costs
HCA Healthcare achieved termination without serving an answer, without a validity ruling, and with each party bearing its own costs. This is a commercially clean exit: no infringement finding, no royalty obligation established on the public record, and no judicial determination of the patents’ scope or validity. The with-prejudice designation provides durable protection against Patent Armory specifically on these five patents.
Clean exit, no liability findingFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Patent Armory, Inc. | Company | Patent assertion entity — holder of US9456086B1 and four further call routing patentsSearch in Eureka ↗ |
| Defendant | HCA Healthcare, Inc. | Company | HCA Healthcare, Inc. — major U.S. for-profit hospital and healthcare services operatorSearch in Eureka ↗ |
| Plaintiff counsel | Isaac Rabicoff | Attorney | Counsel for Patent Armory, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Rabicoff Law LLC | Law Firm | Representing Patent Armory, Inc.Search in Eureka ↗ |
| Defendant counsel | Douglas F. Stewart | Attorney | Counsel for HCA Healthcare, Inc.Search in Eureka ↗ |
| Defendant law firm | Bracewell LLP | Law Firm | Representing HCA Healthcare, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Texas Western District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order confirms that Patent Armory’s dismissal was self-executing under Rule 41(a)(1)(A)(i) — the language ‘self-effectuating and terminates the case in and of itself’ is drawn directly from Fifth Circuit precedent. The with-prejudice designation is plaintiff-initiated, meaning HCA Healthcare bears no judicial finding of infringement or non-infringement. Critically, no claim construction or validity ruling was issued, leaving all five patents legally intact and assertable against other defendants. The cost order — each party bearing its own — is standard for pre-answer Rule 41 dismissals and does not imply bad faith by either party.
US9456086B1 — Intelligent communication routing system and method
US9456086B1 anchors the asserted portfolio and relates to intelligent communication routing systems and methods — technology that governs how inbound calls or communications are directed across large-scale networks, such as hospital contact centres. The application number US12/719827 places its origin in the early smartphone era, a period when intelligent routing architectures were transitioning from hardware-based PBX systems to software-defined models. The portfolio spans multiple continuation-style applications, with grant dates extending from the mid-2000s (US7023979B1, US7269253B1) through to the late 2010s (US10491748B1, US10237420B1), suggesting deliberate layering of claim coverage across technology generations.
For large healthcare organisations operating multi-site contact centres — a core HCA Healthcare infrastructure component — these patents represent meaningful IP risk. The combination of call routing, telephony control, and auction-based entity matching claims is broad enough to implicate both proprietary and vendor-supplied communication platforms. The fact that Patent Armory has assembled a five-patent cluster across different application vintage years is consistent with a portfolio-based assertion strategy designed to complicate prior art defences. Any competitor or peer organisation in the healthcare sector deploying modern ACD, IVR, or AI-driven call routing systems should assess exposure to this portfolio.
Should your team run an FTO analysis against US9456086B1 and the Patent Armory portfolio?
If your organisation operates or procures intelligent call routing systems, telephony control infrastructure, or auction-based communication matching — particularly in healthcare, insurance, or large enterprise environments — this five-patent portfolio warrants a formal freedom-to-operate review. The dismissal with prejudice protects HCA Healthcare alone; it creates no safe harbour for other operators. Vendor contracts and SaaS agreements for contact centre technology should be reviewed for indemnification coverage against this specific portfolio.
PatSnap Eureka’s FTO Search Agent can map each of the five asserted patents against your product’s technical architecture, identify overlapping claim language, and surface prior art that was never tested in this litigation. Because no claim construction order was issued, the scope of ‘intelligent routing’ and ‘telephony control’ claims remains judicially undefined — making a proactive claim-by-claim analysis especially valuable for R&D and procurement teams selecting or building call routing solutions.
Run a freedom-to-operate analysis on US9456086B1 to assess your product’s exposure
Run FTO in Eureka →Similar patent cases: call routing and telephony IP in W.D. Texas
Explore related infringement actions asserting telephony and intelligent call routing patents in the Western District of Texas and comparable federal venues.
What this case signals for the healthcare telephony IP landscape
Rapid with-prejudice dismissals in W.D. Texas patent cases warrant close monitoring — outcomes vary, and the absence of merits rulings leaves key questions open.
With-prejudice dismissals do not resolve patent validity
The five call routing patents remain valid and enforceable against all parties other than HCA Healthcare. Any company deploying intelligent call routing, telephony control, or auction-based entity matching systems should treat these patents as live enforcement risks. No IPR, no claim construction, and no prior art ruling was issued in this case.
Early dismissal before answer is a well-established risk management play
HCA Healthcare’s strategy — or Patent Armory’s pre-answer resolution — resulted in case closure before any substantive litigation costs accrued publicly. For defendants in W.D. Texas, the window before an answer is filed represents a critical leverage period. Monitoring PAE filing patterns in this court is advisable for large healthcare operators.
Patent v HCA — key questions answered
Patent Armory asserted five U.S. patents: US9456086B1, US10491748B1, US7269253B1, US7023979B1, and US10237420B1. The patents cover intelligent communication routing systems and methods, telephony control with intelligent call routing, and a method and system for matching entities in an auction — all relevant to large-scale telephony and contact centre infrastructure.
The case was voluntarily dismissed with prejudice by Patent Armory under Rule 41(a)(1)(A)(i) just 67 days after filing. HCA Healthcare had not yet filed an answer or a motion for summary judgment, making the dismissal self-executing. The public record does not disclose whether a settlement was reached or whether Patent Armory decided not to proceed — both are consistent with a pre-answer resolution of this type.
Yes. A dismissal with prejudice operates as a final adjudication on the merits for purposes of res judicata. Patent Armory is permanently barred from asserting the same claims under US9456086B1, US10491748B1, US7269253B1, US7023979B1, and US10237420B1 against HCA Healthcare. The patents remain enforceable against all other parties — the protection is specific to HCA Healthcare in this action.
No. The case terminated before any merits ruling. There was no claim construction order, no summary judgment on validity, and no trial. The five patents asserted — US9456086B1 and related portfolio — remain presumptively valid and enforceable against parties other than HCA Healthcare. Competitors and technology vendors cannot rely on this dismissal as a validity determination.
The court ordered each party to bear its own costs, expenses, and attorney fees. This is the default outcome for a pre-answer Rule 41(a)(1)(A)(i) voluntary dismissal and does not imply any finding of bad faith, frivolous filing, or exceptional case status under 35 U.S.C. § 285. Neither party obtained a fee award, and the order does not reflect any judicial assessment of the merits of the infringement claims.
PatSnap Eureka searches patents and litigation data to answer instantly.